Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study
pharmafile | June 14, 2016 | News story | Manufacturing and Production, Research and Development | Janssen, blood cancer, drug trial, imbruvica
Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival of 74.8%.
The company said the drug to treat Chronic Lymphocytic Leukaemia (CLL) and mantle cell lymphoma (MCL) also demonstrated a higher overall response rate.
Rozlyn Bekker, medical director of Janssen, said: “The data not only helps improve our understanding of ibrutinib patient populations, but also firmly strengthen the evidence base for the efficacy of the treatment in CLL and MCL.”
Imbruvica is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, which works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B cells. By blocking this BTK protein, ibrutinib helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.
Ibrutinib is currently approved in Europe for the treatment of adult patients with relapsed or refractory MCL, and previously untreated adult patients with CLL.
Anjali Shukla
Related Content
Regeneron plans to share advancements from blood cancer pipeline
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …